Shravan Kumar Sriraman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Shravan Kumar Sriraman has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Alexei Degterev
Department of Biochemistry, Tufts University School of Medicine, Boston, MA 02111, USA
1 shared publication- Can Sarisozen
Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston, MA 02115, USA
1 shared publication Ed Luther
Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston, MA 02115, USA
1 shared publicationGiusseppina Salzano
Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston, MA 02115, USA
1 shared publication- Vananélia P. N. Geraldo
Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston, MA 02115, USA; São Carlos Institute of Physics, University of São Paulo, São Carlos, SP 13566-590, Brazil
1 shared publication - Vladimir P. Torchilin
Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston, MA 02115, USA; Department of Chemical Engineering, Northeastern University, Boston, MA 02115, USA
1 shared publication
Latest Publications
- 1 August 2016
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 105, 40-49
Anti-cancer activity of doxorubicin-loaded liposomes co-modified with transferrin and folic acid
- 1 August 2016
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 105, 40-49
Anti-cancer activity of doxorubicin-loaded liposomes co-modified with transferrin and folic acid
- 1 December 2015
- Published by Elsevier in Journal of Controlled Release
- Vol. 220, 160-168
Cytotoxicity of PEGylated liposomes co-loaded with novel pro-apoptotic drug NCL-240 and the MEK inhibitor cobimetinib against colon carcinoma in vitro
- 1 December 2015
- Published by Elsevier in Journal of Controlled Release
- Vol. 220, 160-168
Cytotoxicity of PEGylated liposomes co-loaded with novel pro-apoptotic drug NCL-240 and the MEK inhibitor cobimetinib against colon carcinoma in vitro